- The situation at Star Scientific (STSI +0.9%) is bleak, according to SA contributor Paulo Santos.
- He thinks the company's desperate measure to raise capital through the issuance of new shares is just buying time with hopes for a revenue bonanza fading.
- The bull case on STSI hinges on the potential for Anatabloc to be a mass market product. The company expects a patent related to the treatment's active ingredient to be granted shortly.
at MarketWatch.com (Nov 12, 2012)